期刊
JOURNAL OF CLINICAL IMMUNOLOGY
卷 33, 期 4, 页码 838-846出版社
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10875-012-9856-z
关键词
Common variable immunodeficiencies; anti-pneumococcal polysaccharide IgM; anti-pneumococcal polysaccharide IgA; ELISA; pneumonia; bronchiectasis
类别
资金
- EUROPAD NET (EC) [201549]
- Italian Ministry of Health, Sapienza University of Rome
- Jeffrey Modell Foundation
- Fondazione Eleonora Lorillard Spencer Cenci
Purpose Existing ways of assessing CVID patients at risk of pulmonary infections are not universally accepted. The need to identify additional prognostic factors allowed us to evaluate the anti-polysaccharide IgA and IgM responses in 125 CVID patients immunized with the 23-valent pneumococcal polysaccharide (PS) vaccine (Pneumovax (R)). Methods We used a new anti-PS23 IgM and IgA ELISA assay, which evaluates a global response to all 23 polysaccharides contained in Pneumovax (R). Results Anti-PS23 IgM and/or IgA antibodies were detectable in a minority of CVID patients. Antibody responses were correlated to B cell subpopulations and serum immunoglobulin concentrations. The non responders had a higher incidence of pneumonia and bronchiectasis and responders had the lowest incidence of respiratory complications. Conclusions This new ELISA assay allows for studying vaccine response in patients on Ig replacement therapy. This test also is an additional method of evaluation of specific antibody responses representing a valuable contribution to identify prognostic marker in CVID patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据